TEL AVIV, Israel--(BUSINESS WIRE)--CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and Thermo Fisher Scientific (NYSE: TMO).

以色列特拉维夫--（商业新闻短讯）--CytoReason是开发预测性疾病模型的领导者，今天宣布它从我们的人群，NVIDIA（纳斯达克：NVDA），辉瑞（纽约证券交易所：PFE）和Thermo Fisher Scientific（纽约证券交易所：TMO）获得了8000万美元的总收入。

CytoReason will use this investment to expand the application of its models into additional indications, grow its proprietary molecular and clinical data, and establish an office in Cambridge, Massachusetts later this year.

CytoReason将利用这项投资将其模型的应用扩展到其他适应症，增加其专有的分子和临床数据，并于今年晚些时候在马萨诸塞州剑桥市设立办事处。

Reduced R&D timelines and improved probability of technical and regulatory success (PTRS) are top priorities across life sciences companies. Speed, safety, and accuracy are critical when making asset-related R&D decisions. CytoReason provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio..

缩短研发时间表和提高技术和监管成功率（PTR）是生命科学公司的首要任务。在做出与资产相关的研发决策时，速度、安全性和准确性至关重要。CytoReason为治疗领域的领导者提供了分子层面的见解和有价值的人工智能工具，以做出数据驱动的决策，帮助他们提高第二阶段成功的可能性并优化其研发组合。。

Since the company announced the expansion of its Pfizer partnership in 2022, CytoReason has added three major pharma partnerships, expanded its coverage of disease models to central nervous system (CNS)-related diseases, and partnered with leading data organizations.

自该公司于2022年宣布扩大其辉瑞合作伙伴关系以来，CytoReason增加了三个主要的制药合作伙伴关系，将疾病模型的覆盖范围扩大到中枢神经系统（CNS）相关疾病，并与领先的数据组织合作。

CytoReason’s technology and scientific breakthroughs are regularly published in top-tier journals such as Nature, Cell, and Gut. In 2023 alone, CytoReason’s scientists published 20 peer-reviewed articles in 16 journals, demonstrating the scientific throughput of the company’s team and technology.

CytoReason的技术和科学突破定期发表在《自然》、《细胞》和《肠道》等顶级期刊上。仅在2023年，CytoReason的科学家就在16种期刊上发表了20篇同行评议的文章，证明了该公司团队和技术的科学吞吐量。

Six of the world’s top ten pharma companies use CytoReason’s technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas.

世界十大制药公司中有六家使用CytoReason的技术在免疫学、炎症、免疫肿瘤学、新陈代谢和其他治疗领域做出数据驱动的决策。

David Harel, Co-founder and CEO of CytoReason, said: “CytoReason is grateful for this infusion of new capital from industry technology powerhouses such as NVIDIA, Pfizer, and Thermo Fisher. The world understands that data alone is not enough, and that the future of data-driven insights is in data modeling.

CytoReason联合创始人兼首席执行官大卫·哈雷尔（David Harel）表示：“CytoReason感谢NVIDIA、辉瑞和赛默飞世尔等行业技术巨头注入的新资本。全世界都明白，仅仅数据是不够的，数据驱动见解的未来在于数据建模。

CytoReason is at the forefront of this revolution in pharma R&D.”.

CytoReason是这场制药研发革命的前沿。”。

Kimberly Powell, Vice President and General Manager, Healthcare at NVIDIA, said: “Over the last year, CytoReason has strengthened its platforms using NVIDIA’s latest accelerated computing and AI platforms, achieving more than 10x acceleration for inference workloads. Our continued collaboration with CytoReason will help enable more life sciences companies to benefit from CytoReason’s predictive clinical insights.”.

NVIDIA医疗保健副总裁兼总经理金伯利·鲍威尔（Kimberly Powell）表示：“去年，CytoReason使用NVIDIA最新的加速计算和人工智能平台加强了其平台，推理工作量加速了10倍以上。我们与CytoReason的持续合作将有助于使更多生命科学公司受益于CytoReason的预测性临床见解。”。

Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, said: “The rapid expansion of new technologies, like artificial intelligence, holds tremendous potential to help transform what is possible in human health. Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients.

辉瑞公司首席科学官兼全球研究、开发和医疗总裁Mikael Dolsten表示：“人工智能等新技术的快速发展具有巨大潜力，有助于改变人类健康的可能性。我们与CytoReason的合作利用其尖端免疫学多组学平台来增强辉瑞公司自身的研发能力，并为患者的新药开发途径产生宝贵的见解。

We’re pleased to see the company’s recent growth and look forward to our continued work together.”.

我们很高兴看到公司最近的增长，并期待着我们继续合作。”。

Bhooshi De Silva, Head of Strategic Capital at Thermo Fisher Scientific, commented on the strategic investment: 'Our investment in CytoReason underscores the significant potential of computational disease models to revolutionize data usage in pharma R&D. By combining Thermo Fisher’s vast data repositories and proven life sciences expertise with CytoReason’s AI technology, we aim to push the boundaries of what is possible in personalized healthcare.”.

赛默飞世尔科技（Thermo Fisher Scientific）战略资本主管布希·德席尔瓦（Bhooshi De Silva）对这项战略投资发表了评论：“我们对CytoReason的投资突显了计算疾病模型的巨大潜力，可以彻底改变制药研发中的数据使用。通过将赛默飞世尔（Thermo Fisher）庞大的数据存储库和成熟的生命科学专业知识与CytoReason的人工智能技术相结合，我们旨在推动个性化医疗保健领域的发展。”。

Jon Medved, CEO of OurCrowd said: 'We're thrilled to see yet another Israeli company leading the way in healthcare's AI revolution. CytoReason’s strategic partnership with NVIDIA only emphasizes this point. I’m convinced that the involvement of leading asset managers and critical strategic partners in this funding round will further propel CytoReason's journey.'.

。CytoReason与NVIDIA的战略合作关系只强调了这一点。我相信，领先的资产管理公司和关键战略合作伙伴参与这轮融资将进一步推动CytoReason的旅程。”。

CytoReason is excited to use this new funding to accelerate its growth and further cement its position in the market. This will enable more pharma and biotech companies to increase the speed and accuracy of asset development across therapeutic areas to benefit more patients worldwide.

CytoReason很高兴利用这一新资金来加速其增长，并进一步巩固其在市场上的地位。这将使更多的制药和生物技术公司能够提高治疗领域资产开发的速度和准确性，从而使全球更多患者受益。

Bank Hapoalim provided structured financing through its Tech Sector, Business Banking Division. Nomura Securities and Locust Walk advised the company in the transaction.

Hapoalim银行通过其技术部门商业银行部门提供结构性融资。野村证券和Locust Walk在交易中为该公司提供咨询服务。

About CytoReason

关于细胞原因

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven, using computational disease models for predictive asset insights. Therapeutic area leaders, research teams, and scientists of all levels rely on CytoReason’s technology to increase the speed and accuracy of R&D decisions.

CytoReason是一家科技公司，使用计算疾病模型预测资产见解，将生物制药的决策从试验和错误转变为数据驱动。治疗领域的领导者、研究团队和各级科学家依靠CytoReason的技术来提高研发决策的速度和准确性。

For example, scientists can prioritize potential targets and indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable insights by comparing their R&D portfolios to treatment alternatives.

例如，科学家可以优先考虑潜在的目标和适应症，并对患者人群进行分层。项目负责人可以比较多种疾病的药物或单一疾病中的多种药物。通过将研发投资组合与治疗方案进行比较，C级高管可以获得有价值的见解。

Learn more at www.cytoreason.com..

。。